earn preview select biotech
earn around corner provid thought select larg mid-cap
biotech compani within coverag overal expect bounceback quarter across
mani compani reignit interest larger-cap biotech even potenti
increas drug price rhetor mid-term elect preview celg
detail estim price target chang
follow page
outperform estimate et expect materi beat caveat
rx trend cf vari degre reliabl inventori dynam
precis quantifi could impact project multipl rx sourc indic symdeko
track sale nearli doubl consensu estim estim vs con
indic strong launchconsist physician feedback recent posit compani
commentaryand particularli given appear modest cannib orkambi
estim vs con mean benefit slightli higher
price per patient switch also effect expand market enabl larger long-
term revenu opportun could see updat full-year cf sale guidanc exampl
strong quartercoupl remov recent competit
overhang expect soon announc complet enrol combo
studi earlier expectedshould make continu strong momentum share
see increasingli clear path toward revenu earn power key risk
remain eu reimburs
outperform et expect signific bounceback quarter hiv
franchis base rx analysi biktarvi notabl strong view track handili
beat consensu estim quarter vs con well year
estimate vs con establish substanti foundat major futur revenu driver
off-set modest weak project truvada descovi hcv track
gener line lower expect vosevi look soft less materi
would expect non-gaap ep quarter slightli consensu could
potenti updat guidanc better reflect hcv/revenues/r track lower end
respect prior guidanc rang overal expect solid reaffirm
base earn growth remind underappreci pipelin would expect see
appreci investor potenti rotat back large-cap biotech
sector perform et tecfidera avonex show good stabil
potenti ex-u spinraza uptak off-set slow growth transit mainten
expect slight top-lin beat vs con revenu ep dynam quarter confound
inclus one-tim ioni payment opex well tax rate uncertainti non-gaap
guidanc run-rat expect greater focu product sale
could see updat guidanc revenu track higher end prior rang closer
vs due bd result ep closer vs solid ms
dynam anticip favor roi potenti samsung bioepi flip increas price target
though greater potenti out-year competit continu page
page cont celg well summari
price target chang
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
earn preview select biotech
continu page
contd spinraza see out-year sale declin peak
aducanamab risk continu look materi bd announcementsa well
announc sma gene therapi entryfor increas growth visibl stock
catalyst especi share come low
celg outperform et expect reason quarter celg
modest bottom-lin beat estim street-high vs con driven strong
otezla potenti abraxan beat help off-set slight soft mm partli due
slow pomalyst script ep also inflat due increas share repurchas
believ yet reflect consensu number believ celg could potenti
updat revenu guidanc upper end prior rang increas ep
guidanc account buyback off-set juno dilut rang encompass
though revlimid patent cliff remain overhang potenti settlement seem
less like next year believ sentiment multipl trough
addit posit pipelin news luspatercept revlimid lymphoma car-t program
and/or pipelin candid help rebuild enthusiasm out-year
revenu driver given compani market cap expect free cash
flow revlimid goe gener continu believ littl valu place
pipelin continu valuat disconnect creat buy opportun
outperform estimate et script sale data suggest gradual modest
increas ocavlia uptak necessarili dramat inflect
hope label updat safeti issu clarifi enabl ww
sale come around consensu estim vs con provid comfort
multi-hundr million dollar pbc foundat even gradual growth potenti
out-year competit believ still establish solid valuat floor despit
recent share upsid expect continu momentum share regener
readout believ accumul evid antifibrot benefit oca
fxr mechan creat high likelihood success upsid potenti
share current level nash success potenti out-year nash sale
believ creat favor risk-reward setup expect stock continu
sector perform estimate et continu project jakafi
sale line consensu estim track reach yearli sale
believ jakafi continu form strong core base busi though
olumi royalti unlik materi near-term potenti pipelin driver still
matur would expect share trade line
outperform estimate et expect exondi maintain q/q
growth trajectori enabl part high complianc rate unproblemat
reauthor discontinu model revenu
multipl catalyst anticip back half includ addit readout
microdystrophin gene therapi program initi first limb girdl gene therapi
trial believ gene therapi enthusiasm drive upward momentum share
remaind year
outperform estimate et script emflaza translarna difficult
track though revenu number came slightli lighter expect due
season unpredict purchas pattern still model uptick sale
reach translarna emflaza revenu approxim consensu
estim total sale believ compani track achiev full-year
earn preview select biotech
guidanc translarna revenu emflaza revenu
continu provid cash pipelin develop bd effort expect
becom increasingli import stori come recent promis data
potenti gener out-year royalti addit data
present later year includ early-octob highlight
view underappreci prospect see share under-valued base
potenti well believ greater resili translarna franchis
long-term even dmd gene therapi reach market
sector perform estimate et expect hcv royalti slightli beat
consensu estim vs consensu base continu steadi mavyret
script believ enabl partner abbv overal hcv revenu
receiv royalti come guidanc quarter critic
determin enta royalti tier discuss previous could enter higher
percentag beyond lower tier given substanti hcv incom
mavyret though depend exact cumul annual sale cut-off
unknown believ much recent upsid attribut assumpt
enter next tier current assum tier everi cumul total annual
sale rais price target believ recent stock
strength warrant think current valuat fairli reflect long-term valu
hcv royalti stream potenti product nash though futur advanc
asset rsv hbv current model given earli stage could drive
upsid matur
outperform specul risk estimate et follow posit result
phase iib storm studi plan file nda penta-refractori mm
request acceler approv potenti launch though
gear potenti selinexor launch signal like
commerci market selinexor without partner expect
increment increas sg spend throughout year senior commerci posit
continu filledth major cost associ launch hire sale forc
plan expect major updat earn
take opportun revamp model better reflect expect futur
commerci dynam assum commerci selinexor mm dlbcl
 rather profit split ultim increas opex provid
favor econom though also moder out-year mm dlbcl sale
estim base evolv competit landscap run-rat product
see potenti out-year selinexor sale oper margin
two-third ww sale expect come plu royalti yield
out-year ep opportun blend dcf assumpt yield new price
target previous valuat believ appropri reflect
realist po adopt potenti selinexor vs stock current trade
stat sell day vs fx eur/usd bp q-o-q unfavor usd
strength biggest potenti beat includ symdeko con biktarvi
con otezla con abraxan con mavyret royalti
con avonex con notabl miss includ vosevi con
atripla con descovi con orkambi con
price target adjust base model updat adjust price target
follow celg
revis rate though recent upgrad outperform
downgrad pti sector perform
earn preview select biotech
estim mm except per share item estimatesconsensu earn preview select biotech
increas sale estim tecfidera avonex plegridi base strong rx trend lower near-
reduc out-year sale spinraza reflect probability-weight potenti compet small molecul splice
modul potenti enter market continu await mid-year entri biib sma gene therapi
clinic better understand potenti long-term sma competit dynam
slightli reduc long-term annual tysabri price increas better reflect greater use extended-interv dose
incorpor exercis option samsung bioepi stake well potenti sale
push back timelin potenti launch stroke slightli base compani guidanc
adjust go-forward tax rate downward base run-rat
biogen inc million except per share rest rest rest rest zinbryta row rest aducanumab probabl opicinumab probabl psp probabl weight stroke probabl weight product revenu total product total research sell gener collabor profit total oper gain sale incom incom expens net net pre-tax incom tax net net loss attribut non-controlling interest- net incom earn per share outstand share outstand celgen celg
earn preview select biotech
celg estim mm except per share item estimatesconsensu earn preview select biotech
rais near- long-term otezla sale estim base strong rx im sale trend
slightli reduc near- long-term pomalyst estim due rx run rate
adjust revlimid near-term estim upward slightli better reflect season pattern
increas abraxan sale base expect pull-through price increas coupl favor im sale trend
increment rais po out-year estim cll base compani commentari analyst day
increas po luspatercept reflect posit medalist md trial result
reduc out-year ozanimod sale ms base unfavor physician feedback competit place
lower near-term out-year revlimid price increas due evolv pricing/reimburs landscap recent
compani commentari price rais limit
reduc termin growth rate modestli better account potenti gener dynam pipelin reward/risk
celgen celg million except per share includ program citarinostat net product good research sell gener total oper oper interest invest incom net- interest expens incom expens net net pre-tax incom tax net earn per share outstand share outstand gilead
earn preview select biotech
estim mm except per share item estimatesconsensu earn preview select biotech
descovi
believ better
increas po
filgotinib uc base
recent favor
adjust hiv
base rx trend
lower legaci
estim atripla
truvada
fx rate
million except per share antivir hcv harvoni- unit states- europe- international- epclusa- unit states- europe- international- unit international- vosevi- unit states- europe- international- total hiv genvoya e/c/f/taf unit states- europe- international- unit unit unit international- unit unit descovi f/taf unit states- europe- international- odefsey r/f/taf unit states- europe- international- biktarvi unit europe- international- antivir includ unit zydelig- product includ filgotinib prob-adjust prob-adjust selonsertib combo prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
estim mm except per share item estimatesconsensu estimatesactualnotesjakafi earn preview select biotech
discret model two addit pipelin program fgfr contribut potenti topic
ruxo ad vitiligo probability-adjust
increas po jakafi acut gvhd follow posit reach data
reduc baricitinib market opportun ra due restrict label fda reject mg dose
addit lower baricitinib po indic sle dose like essenti
incom statement thousand except share royalties- sale probability-blend iclusig net eu revenu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust pipelin revenu prob-adjust product fair valu acq-rel conting cost incom unreal gain loss long-term debt exchang net pre-tax benefit incom incom per share outstand share outstand vertex
earn preview select biotech
estim mm except per share item estimatesconsensu cf earn preview select biotech
increas near- medium-term sale estim symdeko base prescript trend suggest faster
expect uptak off-set slightli lower orkambi estim account cannib
slightli rais out-year cf franchis penetr estim reflect increas likelihood high market
penetr given recent setback competitor
lower near- long-term ex-u cf franchis sale estim market penetr better reflect potenti
reimburs risk remain
thousand except per share tez/iva combo- product revenu revenu product oper expens incom net- pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand intercept
earn preview select biotech
adjust near-term ocaliva pbc sale slightli base modest q-o-q script growth
modestli reduc out-year ocaliva pbc growth account potenti gener brand competit
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva ocaliva nash licens total revenu cost sales- research sell gener stock-bas total oper incom interest expense- interest incom net pre-tax incom tax provision- net earn per share outstand share outstand sarepta
earn preview select biotech
estim mm except per share item estimatesconsensu estimatesactualnotesexondi earn preview select biotech
follow initi biomark data present sarepta day increas likelihood success
microdystrophin gene therapi program
adjust exon-skip oligo therapi penetr account cannib gene therapi
ad probability-adjust estim limb girdl muscular dystrophi model
sarepta inc thousand except per share eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- myonexu gene therapy- eu- research contract total good gener in-licens exondi litig licens oper incom sale intang incom chang warrant incom comprehens incom incom incom enanta
earn preview select biotech
increas hcv royalti base strong mavyret prescript trend
increment increas po given accumul evid like fxr benefit nash
earn preview select biotech
incom thousand except royalti sale pbc nash revenu good gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end earn preview select biotech
revis likelihood success sma follow promis firefish data
increas total market penetr increas price assumpt
modifi revenu build discret model type type type sma patient
inc thousand except per share grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom earn preview select biotech
assum commerci market selinexor without partnerremov profit
split -base mileston payment increas sg reflect cost associ launch
moder potenti market opportun mm dlbcl reflect evolv competit landscap
karyopharm thousand except share selinexor sales- selinexor royalties- grant revenu good sold- gener oper incom pre-tax tax provision- net incom per share outstand share outstand dilut appendix
earn preview select biotech
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest aducanumab probabl opicinumab probabl psp probabl weight stroke probabl weight product revenu total product total research sell gener collabor profit total oper gain sale incom incom expens net net pre-tax incom tax net net loss attribut non-controlling interest- net incom earn per share outstand share outstand
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest aducanumab probabl opicinumab probabl psp probabl weight stroke probabl weight product revenu total product total research sell gener collabor profit total oper gain sale incom incom expens net net pre-tax incom tax net net loss attribut non-controlling interest- net incom earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv dcf use discount rate termin growth rate appli
follow tecfidera patent expiri valuat support sector perform rate
risk rate price target risk includ failur major clinic program like aducanumab competit price
pressur ms competit sma
earn preview select biotech
celgen celg million except per share includ program citarinostat net product good research sell gener total oper oper interest invest incom net- interest expens incom expens net net pre-tax incom tax net earn per share outstand share outstand celg
earn preview select biotech
celgen celg million except per share includ program citarinostat net product good research sell gener total oper oper interest invest incom net- interest expens incom expens net net pre-tax incom tax net earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target base dcf analysi use discount rate termin growth rate
slightli higher use peer reflect greater pipelin depth beyond revlimid cliff valuat justifi
outperform rate celg
risk rate price target risk includ increas price pressur multipl myeloma earlier-than-expect
generic revlimid failur pipelin product ozanimod luspatercept competit
earn preview select biotech
million except per share antivir hcv harvoni- unit states- europe- international- epclusa- unit states- europe- international- unit international- vosevi- unit states- europe- international- total hiv genvoya e/c/f/taf unit states- europe- international- unit unit unit international- unit unit descovi f/taf unit states- europe- international- odefsey r/f/taf unit states- europe- international- biktarvi unit europe- international- antivir includ unit zydelig- product includ filgotinib prob-adjust prob-adjust selonsertib combo prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
million except per share antivir hcv harvoni- unit states- europe- international- epclusa- unit states- europe- international- unit international- vosevi- unit states- europe- international- total hiv genvoya e/c/f/taf unit states- europe- international- unit unit unit international- unit unit descovi f/taf unit states- europe- international- odefsey r/f/taf unit states- europe- international- biktarvi unit europe- international- antivir includ unit zydelig- product includ filgotinib prob-adjust prob-adjust selonsertib combo prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv via dcf analysi discount rate termin growth rate
post-taf gener valuat support outperform rate
risk rate price target risk includ gener hiv entrant competit hcv efficaci safeti risk
pipelin product filgotinib selonsertib axi-cel
earn preview select biotech
thousand except per share tez/iva combo- product revenu revenu product oper expens incom net- pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand
earn preview select biotech
thousand except per share tez/iva combo- product revenu revenu product oper expens incom net- pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv dcf analysi base busi discount rate
termin growth rate price target support outperform rate
risk rate price target risk includ lower expect commerci uptak tez/iva price pressur cf
competit emerg safeti issu tripl combo
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva ocaliva nash licens total revenu cost sales- research sell gener stock-bas total oper incom interest expense- interest incom net pre-tax incom tax provision- net earn per share outstand share outstand
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva ocaliva nash licens total revenu cost sales- research sell gener stock-bas total oper incom interest expense- interest incom net pre-tax incom tax provision- net earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-
adjust multipl adjust ep discount analys price target support outperform rate
risk rate price target risk includ failur demonstr efficaci nash psc new drug-rel safeti
signal emerg unexpect increas frequenc death liver injuri signal potenti drug-rel toxic
challeng control therapeut window trial real-world set pruritu unmanag cholesterol increas
stagnant growth pbc due label chang conservat among physician uncertainti epidemiolog restrict
reimburs remov market competit agent
earn preview select biotech
incom thousand except royalti sale pbc nash revenu good gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end
earn preview select biotech
incom thousand except royalti sale pbc nash revenu good gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-
adjust multipl adjust ep discount analys valuat support sector perform
risk rate price target risk includ competit hcv nash/pbc price pressur hcv potenti
safeti signal emerg poor efficaci futur studi
earn preview select biotech
karyopharm thousand except share selinexor sales- selinexor royalties- grant revenu good sold- gener oper incom pre-tax tax provision- net incom per share outstand share outstand dilut
earn preview select biotech
karyopharm thousand except share selinexor sale assum profit split selinexor royalties- grant revenu gener oper incom pre-tax tax provision- net incom per share outstand share outstand dilut earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-adjust
price-to-earnings multipl adjust discount analys valuat support outperform specul risk
rate assign specul risk rate given unpredict futur revenu expens non-revenu gener
statu stock price volatil could result substanti upside/downsid swing anticip valuat
risk rate price target risk includ emerg safeti signal selinexor failur show consist efficaci
signal storm sadal boston selinexor studi toler issu limit ultim market uptak
earn preview select biotech
